Responses
Clinical and epidemiological research
Extended report
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Compose a Response to This Article
Other responses
No responses have been published for this article.